A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Baltaleucel-T (Primary) ; Asparaginase; Brentuximab vedotin; Dexamethasone; Gemcitabine; Oxaliplatin; Pralatrexate; Prednisone; Rituximab; Vinorelbine
Indications Extranodal NK-T-cell lymphoma
Focus Therapeutic Use
Acronyms CITADEL
Sponsors Kuur Therapeutics

10 Mar 2020 According to an Kuur Therapeutics media release, Cell Medica has changed its name to Kuur Therapeutics.
10 Jan 2019 Status changed from recruiting to discontinued.
12 Dec 2017 Results (n=11, data cut off:31 Jul 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com